Prostate Cancer

They are the cheapest form of social insurance you can buy for yourself. Carry Big Brother in your pocketAnd He said: Share thy files with thy neighbourNightmare long after ChristmasInstant message in a bottleVirus could mutate, infect millionsWear your tech on your sleeveMoving software towards the WebDungeon Siege 2 stays close to originalBody Worlds raises ethical concerns Excalibur Elite Eight electionsPlayer attends CFL evaluation campParalympic Games deserve equal recognitionMontreal to Turin for ParalympicsHoop dreams come to a haltKinesiology students pass the torchBeauty in eyes of beheldHow do you stay healthy?

The Marauders raid the Lions The Food Supplement - 2006 Editorial / Opinions No more tax cutsHate the sin, not the sinnerBeing a feminist and a MuslimPartnering religion with raceBuilding a ‘free’ future‘That’s gay’ is passeHealth care system lacking Features Denial of education and religious freedomBringing a worldwide end to violence against womenAgeism and the invisible minorityHow old are you?

From Excalibur to the Gemini AwardsEmbrace that geeky fan-loveGeeks vs.

nerds: Who is who Who's Online We have 43 guests online OPTIMIZED FOR IE 6.0 OR GREATER | COPYRIGHT © EXCALIBUR 2004.

ALL RIGHTS...

When the researchers gave mice with skin cancer a drug that blocked RANKL, the rodents had fewer tumours in their bones than animals that were not treated.

But the drug did not slow the spread of the cancer to other sites in the body.

Prof Penninger and his colleagues stressed that the research was done in mice but they added that drugs that interfere with RANKL are in development which could be used test their findings and show it the same holds true for humans.

"This is an idea that can be directly tested," Prof Penninger said.

Nearly all breast cancer tumours in women have the receptor for RANKL which Prof Penninger said is an indirect indication that the findings are relevant to humans.

"Since there are novel inhibitors of RANKL far along in clinical development, the idea is that people who have cancer that is known to spread to bone can start taking this drug when they are diagnosed," said D.

Holstead Jones, of the University of Toronto and the lead author of the study.

"It would inhibit how much bone metastases they would have," he said in a statement.

Every year an estimated one million people develop metastases to the bones, particularly women with breast cancer.

Drugs that inhibit RANKL may also help to alleviate the severe pa...

This story and its comments expire 30 days after original publication date.

Page 1 of 1 Wired News: Contact Us Subscribe We are translated daily into Korean and Japanese © Copyright 2006, Lycos, Inc.

All Rights Reserved.

Lycos® is a registered trademark of Carnegie Mellon University.

Your use of this website constitutes acceptance of the Lycos Privacy Policy and Terms & Conditions Note: You are reading this message either because you can not see our css files (served from Lygo, a Lycos image server, for performance reasons), or because you do not have a standards-compliant browser.

Read our design notes for details.

...